Choroidal Melanoma

The choroid in the eye is part of the uveal tract. This is made up of the colored iris, the ciliary body, and the choroid. All are rich in melanocytes, the specialized cells that produce melanin. This pigment is a dark-colored, light-absorbing particle.

A melanoma is a tumor which arises from these cells. Melanomas of the eye may be anterior (of the iris) or posterior (of the choroid or ciliary body).

Most of these are choroidal melanomas, which are the most common primary intraocular malignancies. The incidence is 6 per million in the USA.

The choroid is a dark layer that underlies the retina, the neurosensory layer of the eye. Most uveal melanomas are choroidal in origin. Choroidal melanomas typically appear as brown, elevated dome-shaped tumors in the subretinal space with associated retinal detachment, especially if the tumors are over 4 mm in diameter. However, the color may range from totally colorless or amelanotic (rare) to deeply pigmented (most commonly).

Symptoms

Choroidal melanomas are usually asymptomatic or silent tumors. In a few cases, the tumor may impinge on the lens or the fovea, or cause retinal detachment, all of which result in decreased visual acuity or blurring of vision. Most often they are detected during a routine eye examination.

However, sometimes their enlargement may cause retinal detachment, with blurring of vision or decreased visual acuity. Serous detachment occurs at times. Another complication is secondary glaucoma which arises due to closure of the drainage angles by extensive detachment of the retina.

Uveal melanoma - Image Copyright: Alila Medical Media / Shutterstock
Uveal melanoma - Image Copyright: Alila Medical Media / Shutterstock

Risk Factors

The following factors increase the risk of developing a choroidal melanoma:

  • Fair skin
  • Blond or red hair
  • Blue or green eyes

The incidence of these tumors is higher at older ages. It is also high in individuals with the following conditions:

  • Atypical nevus
  • Dysplastic nevus syndrome
  • Melanocytosis, either ocular or oculodermal
  • Certain genetic mutations

Diagnosis and Management

In most choroidal melanomas, the lack of symptoms means that they are detected during a detailed dilated eye examination. Indirect ophthalmoscopy is the most important tool in the evaluation of suspected choroidal melanomas. This is combined with slit lamp examination and gonioscopy.

Uveal melanomas may mimic benign nevi. When they are small, observation may be preferred to watch for progressive growth, which is the mark of a melanoma. Larger tumors require careful examination, especially for the following signs which indicate a higher risk of malignancy:

  • Tumor more than 2 mm thick
  • The presence of subretinal fluid
  • Vision-related symptoms
  • The presence of orange pigmentation (lipofuscin) on the surface of the lesion
  • The tumor margin is in contact with the optic nerve head in front

Since both a choroidal nevus and an early choroidal melanoma appear similar, a fine needle aspiration biopsy is sometimes taken, especially if treatment is considered necessary. However, the results are by no means infallible. Moreover, there is a risk of seeding malignant cells with this technique. Thus initial observation for the growth pattern of the tumor may be preferred if the melanoma is small and there are no indications of malignant growth.

Other investigations to establish the diagnosis include fluorescein angiography and ultrasonography of the eye. Optical coherence tomography and autofluorescence have also been used. It is important to follow up choroidal nevi as almost 9% of them progress to malignant melanomas within 5 years. At 10 years, this is approximately 13% and at 15 years, about 17%.

The primary treatment for a choroidal melanoma is radiotherapy using a radioactive plaque. This technique involves suturing a small gold carrier containing radioactive seeds to destroy the tumorous cells. For more advanced tumors, enucleation of the eye is required, with postoperative radiotherapy if indicated by pathologic and clinical findings.

 

Prognosis

The aggressive nature of a melanoma of the choroid may be predicted using several variables:

  • The cellular components, with epithelioid cells having a worse outcome than spindle celled types
  • Tumor size
  • The anterior extent of the tumor
  • Involvement of the ciliary body
  • Extraocular spread
  • Histopathologic features like mitotic activity and lymphocytic infiltration

The mortality rate goes up with the incidence of recurrence, metastasis, and involvement of the extraocular tissues. Almost 30% of choroidal tumors with metastasis are associated with a fatal outcome within 5 years.

References

Further Reading

Last Updated: Jan 2, 2023

Dr. Liji Thomas

Written by

Dr. Liji Thomas

Dr. Liji Thomas is an OB-GYN, who graduated from the Government Medical College, University of Calicut, Kerala, in 2001. Liji practiced as a full-time consultant in obstetrics/gynecology in a private hospital for a few years following her graduation. She has counseled hundreds of patients facing issues from pregnancy-related problems and infertility, and has been in charge of over 2,000 deliveries, striving always to achieve a normal delivery rather than operative.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, Liji. (2023, January 02). Choroidal Melanoma. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/health/Choroidal-Melanoma.aspx.

  • MLA

    Thomas, Liji. "Choroidal Melanoma". News-Medical. 31 October 2024. <https://www.news-medical.net/health/Choroidal-Melanoma.aspx>.

  • Chicago

    Thomas, Liji. "Choroidal Melanoma". News-Medical. https://www.news-medical.net/health/Choroidal-Melanoma.aspx. (accessed October 31, 2024).

  • Harvard

    Thomas, Liji. 2023. Choroidal Melanoma. News-Medical, viewed 31 October 2024, https://www.news-medical.net/health/Choroidal-Melanoma.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Gene editing restores treatment sensitivity in melanoma